USA - NYSEARCA:CCEL - US2288951088 - Common Stock
The current stock price of CCEL is 4.5139 USD. In the past month the price decreased by -1.51%. In the past year, price decreased by -36.62%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| CVS | CVS HEALTH CORP | 12.97 | 104.26B | ||
| CI | THE CIGNA GROUP | 10.98 | 82.32B | ||
| LH | LABCORP HOLDINGS INC | 17.15 | 21.58B | ||
| BTSGU | BRIGHTSPRING HEALTH SERV - BTSG 6 3/4 02/01/27 | 207.87 | 20.25B | ||
| DGX | QUEST DIAGNOSTICS INC | 18.27 | 19.94B | ||
| FMS | FRESENIUS MEDICAL CARE-ADR | 13.34 | 15.90B | ||
| HIMS | HIMS & HERS HEALTH INC | 58.9 | 10.65B | ||
| DVA | DAVITA INC | 13.38 | 9.27B | ||
| GH | GUARDANT HEALTH INC | N/A | 8.68B | ||
| CHE | CHEMED CORP | 19.62 | 6.40B | ||
| RDNT | RADNET INC | 219.72 | 6.08B | ||
| BTSG | BRIGHTSPRING HEALTH SERVICES | 61.82 | 6.02B |
Cryo-Cell International, Inc. is cord blood bank, which engages in providing stem cell cryopreservation services and advancing regenerative medicine. The company is headquartered in Oldsmar, Florida and currently employs 82 full-time employees. The firm operates through three segments: cellular processing and cryogenic storage for family use, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells; manufacture of PrepaCyte CB Processing System (PrepaCyte CB) units, the processing technology used to process umbilical cord blood stem cells, and cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The firm stores approximately 240,000 cord blood and cord tissue specimens. The specimens are stored in commercially available cryogenic storage units at its technologically and operationally advanced facility. The firm markets its cord blood stem cell preservation services directly to expectant parents and by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals.
CRYO-CELL INTL INC
700 Brooker Creek Blvd, Suite 1800
Oldsmar FLORIDA US
CEO: David Portnoy
Employees: 84
Phone: 18137492104
Cryo-Cell International, Inc. is cord blood bank, which engages in providing stem cell cryopreservation services and advancing regenerative medicine. The company is headquartered in Oldsmar, Florida and currently employs 82 full-time employees. The firm operates through three segments: cellular processing and cryogenic storage for family use, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells; manufacture of PrepaCyte CB Processing System (PrepaCyte CB) units, the processing technology used to process umbilical cord blood stem cells, and cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The firm stores approximately 240,000 cord blood and cord tissue specimens. The specimens are stored in commercially available cryogenic storage units at its technologically and operationally advanced facility. The firm markets its cord blood stem cell preservation services directly to expectant parents and by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals.
The current stock price of CCEL is 4.5139 USD. The price decreased by -1.23% in the last trading session.
CRYO-CELL INTL INC (CCEL) has a dividend yield of 19.53%. The yearly dividend amount is currently 0.25.
CCEL has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
CCEL stock is listed on the NYSE Arca exchange.
7 analysts have analysed CCEL and the average price target is 8.67 USD. This implies a price increase of 92.07% is expected in the next year compared to the current price of 4.5139.
CRYO-CELL INTL INC (CCEL) operates in the Health Care sector and the Health Care Providers & Services industry.
ChartMill assigns a technical rating of 1 / 10 to CCEL. When comparing the yearly performance of all stocks, CCEL is a bad performer in the overall market: 90.7% of all stocks are doing better.
ChartMill assigns a fundamental rating of 3 / 10 to CCEL. There are concerns on the financial health of CCEL while its profitability can be described as average.
Over the last trailing twelve months CCEL reported a non-GAAP Earnings per Share(EPS) of -0.02. The EPS increased by 98.2% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -0.27% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
7 analysts have analysed CCEL and the average price target is 8.67 USD. This implies a price increase of 92.07% is expected in the next year compared to the current price of 4.5139.
For the next year, analysts expect an EPS growth of -100% and a revenue growth -0.13% for CCEL